Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone
| Autor: | Gelders Yg, Marie-Lise J. A. Hoppenbrouwers, André Reyntjens, Paul A. J. Janssen, Dominique L. S. Ceulemans |
|---|---|
| Rok vydání: | 1985 |
| Předmět: |
Adult
Male Pilot Projects Setoperone Pyrimidinones Pharmacology Dysphoria chemistry.chemical_compound Basal Ganglia Diseases Dopamine medicine Humans 5-HT receptor Aged Psychiatric Status Rating Scales Middle Aged medicine.disease Blockade chemistry Schizophrenia Dopamine receptor Female Serotonin Antagonists Serotonin medicine.symptom Psychology medicine.drug |
| Zdroj: | Psychopharmacology. 85:329-332 |
| ISSN: | 1432-2072 0033-3158 |
| Popis: | The new antipsychotic drug setoperone is pharmacologically characterized by its potent serotonin and moderate dopamine receptor blocking properties. Forty chronic schizophrenic patients were included and 34 completed this pilot study. Following a drug-free period of 1 week the patients received setoperone 5 mg t.i.d. After 1 month of treatment, the psychotic symptoms, as measured by the BPRS, improved by approximately 50% (P less than 0.001) as compared with the condition under previous neuroleptic medication. Blockade of serotonin receptors may be related to improvement of autistic behaviour, dysphoria, and parkinson-like symptoms. In residual schizophrenic patients, the need for dopamine blockade, which is normally correlated with the therapeutic effect on positive symptoms, can be reduced substantially. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink